Advertisement
Research ArticleEndocrine and Diabetes

Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas

Ryo Ito, Yoshiyuki Tsujihata, Masami Suzuki, Kazumasa Miyawaki, Kae Matsuda and Koji Takeuchi
Journal of Pharmacology and Experimental Therapeutics April 2016, 357 (1) 217-227; DOI: https://doi.org/10.1124/jpet.115.230730

Article Information

vol. 357 no. 1 217-227
DOI 
https://doi.org/10.1124/jpet.115.230730
PubMed 
26813930
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received November 25, 2015
  • Accepted January 21, 2016
  • Published online March 16, 2016.

Article Versions

Copyright & Usage 
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Ryo Ito,
  2. Yoshiyuki Tsujihata,
  3. Masami Suzuki,
  4. Kazumasa Miyawaki,
  5. Kae Matsuda, and
  6. Koji Takeuchi
  1. Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
  1. Address correspondence to:
    Ryo Ito, Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-higashi 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan. E-mail: ryo.ito{at}takeda.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: January 2016 to November 2023

AbstractFullPdf
Jan 201695051
Feb 20161550142
Mar 20163401370
Apr 20161281122
May 2016641319
Jun 2016631120
Jul 201656723
Aug 2016701229
Sep 201658815
Oct 201665108
Nov 2016752120
Dec 20163765
Jan 20175379
Feb 201763135
Mar 201715166
Apr 201722913
May 201712317
Jun 201783220
Jul 201713630
Aug 201713013
Sep 201722314
Oct 201703525
Nov 201753225
Dec 201704012
Jan 201843015
Feb 201853010
Mar 201872812
Apr 201812121
May 201823426
Jun 201812119
Jul 201802116
Aug 201802817
Sep 201803116
Oct 201813928
Nov 201803131
Dec 201803334
Jan 201922618
Feb 201934019
Mar 201911815
Apr 201922210
May 201912628
Jun 201912011
Jul 201912129
Aug 20190917
Sep 201921822
Oct 201901611
Nov 201911516
Dec 20192138
Jan 2020299
Feb 20201157
Mar 20201147
Apr 2020088
May 20203178
Jun 2020186
Jul 20200148
Aug 20200104
Sep 20203108
Oct 20201119
Nov 202071311
Dec 20204119
Jan 20212913
Feb 202171414
Mar 20219108
Apr 2021488
May 202116107
Jun 2021077
Jul 20213411
Aug 202131413
Sep 2021255
Oct 202111022
Nov 20213726
Dec 20213104
Jan 20222827
Feb 2022576
Mar 2022161510
Apr 202215919
May 20221810
Jun 202211521
Jul 20222910
Aug 202241216
Sep 202221125
Oct 202211112
Nov 2022359
Dec 202231111
Jan 20234119
Feb 2023095
Mar 202341112
Apr 20234715
May 20233916
Jun 202381115
Jul 20231912
Aug 20235513
Sep 2023066
Oct 20233712
Nov 202351211

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleEndocrine and Diabetes

Differentiation between GPR40 Agonists and Sulfonylureas

Ryo Ito, Yoshiyuki Tsujihata, Masami Suzuki, Kazumasa Miyawaki, Kae Matsuda and Koji Takeuchi
Journal of Pharmacology and Experimental Therapeutics April 1, 2016, 357 (1) 217-227; DOI: https://doi.org/10.1124/jpet.115.230730
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement